1475P Results of a randomized, double-blind, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel ± olaratumab in treatment-naïve patients with unresectable metastatic pancreatic cancer

Abstract

Platelet-derived growth factor receptor alpha (PDGFRα) is overexpressed in pancreatic cancer (PC) and contributes to activation of pancreatic stellate cells and formation of characteristic desmoplastic stroma. Despite availability of treatments, PC has a poor prognosis, indicating an unmet need for novel therapies. This study evaluated the efficacy and safety of olaratumab (OLA), an anti-PDGFRα recombinant human immunoglobulin G subclass 1–type monoclonal antibody with standard first-line therapy gemcitabine and nab-paclitaxel in treatment-naïve patients (pts) with unresectable metastatic PC.